(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056314 A3

(51) International Patent Classification[7]: A61K 38/00

(21) International Application Number:
PCT/US2003/040538

(22) International Filing Date:
17 December 2003 (17.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/322,266	17 December 2002 (17.12.2002)	US
60/493,226	7 August 2003 (07.08.2003)	US
60/501,170	8 September 2003 (08.09.2003)	US
60/510,785	10 October 2003 (10.10.2003)	US
60/517,290	4 November 2003 (04.11.2003)	US
60/518,812	10 November 2003 (10.11.2003)	US

(71) Applicant *(for all designated States except US)*: **NASTECH PHARMACEUTICAL COMPANY INC.** [US/US]; 3450 Monte Villa Parkway, Bothell, WA 98021-8906 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **QUAY, Steven, C.** [US/US]; 23632 Hwy 99, Ste. F PMB 454, Edmonds, WA 98026-9224 (US). **BRANDT, Gordon** [US/US]; 790 Kalmia Ct., Issaquah, WA 98027 (US). **KLEPPE, Mary, S.** [US/US]; P.O. Box 1535, Kingston, WA 98346 (US). **MACEVILLY, Conor, J.** [US/US]; 3046 N.W. 60th Street, Seattle, WA 98107 (US).

(74) Agent: **LUNN, Paul, G.**; Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA 98021-8906 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
31 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY

(57) Abstract: Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C_{max}) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.

WO 2004/056314 A3